Transient interruption of arterial thrombosis by inhibition of factor Xa results in long-term antithrombotic effects in baboons

Thrombosis and Haemostasis

Volumn 77, Issue 6, 1997, Pages 1137-1142

  Kotze H F ^a,b   Lamprecht, S ^a   Badenhorst, P N ^a   Roodt, J P ^a   Van Wyk, V ^a  

^a UNIVERSITY OF THE FREE STATE   (South Africa)

^b Department of Haematology ^*  (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 10A; RECOMBINANT TICK ANTICOAGULANT PEPTIDE; THROMBIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTERIOVENOUS SHUNT; ARTERY THROMBOSIS; ARTICLE; BABOON; CONTROLLED STUDY; DACRON VASCULAR PROSTHESIS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; THROMBIN TIME; THROMBOCYTE; THROMBOCYTE LIFESPAN; THROMBOGENESIS;

EID: 0030811328     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1656126     Document Type: Article

References (25)

1. Wietz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-91.
2. Eisenberg PR, Siegel JE, Abendschein DR, Miletich JP. Importance of factor Xa in determining the progoagulant activity of whole blood clots. J Clin Invest 1993; 91: 1877-83.
3. Cadroy Y, Harker LA. Platelets, thrombosis and antithrombotic therapies. In: Cardiovascular Pharmacology, 3rd ed. Antonaccio M, ed. Raven Press, Publishers, New York, N.Y. 1990; pp 515-39.
4. Kelly AB, Marzec UM, Krupski W, Bass A, Cadroy Y, Hanson SR, Harker LA. Hirudin interruption of heparin-resistant arterial thrombus formation in baboons. Blood 1991; 77: 1066.
5. Schaffer LW, Davidson JT, Vlasuk GP, Siegl PKS. Antithrombotic efficacy of recombinant tick anticoagulant peptide; a potent inhibitor of coagulation factor Xa in a primate model of arterial thrombosis. Circulation 1991; 84: 1741-8.
6. Waxman L, Smith DE, Arcuri KE, Vlasuk GP. Tick anticoagulant peptide is a novel inhibitor of blood coagulation factor Xa. Science 1990; 248: 593-6.
7. Jordan SP, Waxman L, Smith DE, Vlasuk GP. Tick anticoagulant peptide: kinetic analysis of the recombinant inhibitor with blood coagulation factor Xa. Biochemistry 1990; 29: 11095-9.
8. Lynch JJ, Sitko GR, Mellot MJ, Nutt EM, Lehman ED, Friedman PA, Dunwiddle T, Vlasuk GP. Maintenance of coronary artery patency following thrombolysis with front load plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition. Cardiovasc Res 1994; 28: 78-85.
9. Vlasuk GP, Ramjit D, Fujita T, Dunwiddle CT, Nutt EM, Smith DE, Shebuski RJ. Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors antistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis. Thromb Haemost 1991; 65: 275-62.
10. Kotzé HF, Lamprecht S, Badenhorst PN. A four hour infusion of r-hirudin results in long-term inhibition of arterial-type thrombosis in baboons. Blood 1995; 85: 3158-63.
11. Hanson SR, Kotzé HF, Savage B, Harker LA. Platelet interactions with Dacron vascular grafts. A model of acute thrombosis in baboons. Arteriosclerosis 1985; 5: 595-603.
12. Hanson SR, Harker LA. Baboon models of acute arterial thrombosis. Thromb Haemost. 1987;5 8: 801-5.
13. 2CL). Proc Natl Acad Sci USA 1988; 85: 3184-8.
14. 111In-labelled platelets in baboons. Blood 1986; 68: 386-93.
15. 2-receptor antagonist. Thromb Haemost 1993; 70: 672-5.
16. 111indium. J Nucl Med. 1991; 32: 62-6.
17. 111In-platelets in the baboon. I. Isolation and labelling of a viable and representative platelet population. Thromb Haemost 1985; 53: 404-7.
18. Nagai H, Handa M, Kawai Y, Watanabe K, Ikeda Y. Evidence that plasma fibrinogen and platelet membrane GP IIB/IIIA are involved. Thromb Res 1993; 71: 467-77.
19. Gemmel CH, Ramirez SM, Yeo EL, Sefton MV. Platelet activation in whole blood by artificial surfaces: Identification of platelet-derived micro-particles and activated platelet binding to leucocytes as material induced activation events. J Lab Clin Med 1995; 125: 276-87.
20. Packham M. Platelet function inhibitors. Thromb Haemost 1983; 50: 610-9.
21. Hanson SR, Kotzé HF, Pieters H, Heyns A du P. Analysis of In-111-platelet kinetics and imaging in patients with aortic grafts and abdominal aneurysms. Arteriosclerosis 1990; 10: 1037-44.
22. Harker LA, Hanson SR, Runge MS. Thrombin hypothesis of thrombus generation and vascular legion formation. Am J Cardiol 1995; 75: 12B-7B.
23. 2Cl in baboons. Blood 1993; 81: 1762-70.
24. Fuster V, Chesebro JH, Badimon L, Offord KP, Wahner HW. Platelet survival. In: Measurement of Platelet Function. Harker LA, Zimmerman TS (eds). Churchill-Livingston, New York, N.Y. 1983: pp 189-215.
25. Kotzé HF, Heyns A du P, Van Wyk V, Steyn JG, Duyvené De Wit LJ, Badenhorst PN. The sensitivity of tests to detect in vivo platelet activation induced by the removal of arterial endothelium of the baboon (Papio ursinus). S Afr Med J 1990; 78: 271-6.